Navigation Links
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
Date:9/12/2011

TA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who have severe kidney problems and should be used with caution in people who have had a kidney transplant. Patients should talk with their healthcare provider if they have severe problems with their stomach, such as delayed emptying of the stomach (gastroparesis) or problems with digesting food. Antibodies may develop with use of BYETTA. Patients who develop high titers to exenatide could have worsening or failure to achieve adequate glycemic control. Consider alternative therapy if this occurs. Severe allergic reactions can happen with BYETTA. There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA or any other antidiabetic drug.

The most common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea most commonly happens when first starting BYETTA, but may become less over time.

These are not all the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For additional important safety information about BYETTA, please see the full Prescribing Information (www.byetta.com/pi) and Medication Guide (www.byetta.com/mg). About Amylin, Lilly and AlkermesAmylin and Lilly partnered to develop and market BYDUREON, which is based on proprietary technology for long-acting medications developed by Alkermes, Inc. BYDUREON is approved in the EU and is under regulatory review in the U.S.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin's research and de
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015  Oticon, Inc. is now accepting nominations for ... awards program, now in its 17 th year, ... demonstrate that hearing loss does not limit a person,s ... People with any degree of hearing loss – from ... four categories earn cash prizes, donations to their favorite ...
(Date:5/28/2015)... ALBANY, N.Y. , May 28, 2015 /PRNewswire/ ... "503B Outsourcing Facility" under section 503B of the ... for this title, the company is subject to ... oversight, producing bulk medications according to the highest ... 21 CFR Part 211. To continuously comply with ...
(Date:5/28/2015)... VIEW, Calif. , May 28, 2015 /PRNewswire/ ... informatics market, Frost & Sullivan recognizes Lexmark ... & Sullivan Award for Company of the Year ... to take HCM to the next level of ... strategic acquisitions and followed them up with large-scale ...
Breaking Medicine Technology:2015 Oticon Focus on People Awards Seek Outstanding People with Hearing Loss For National Recognition and Prizes 2Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 2Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 3Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 4Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 5
... LAKE FOREST, Ill., March 5, 2012  RoundTable Healthcare ... exclusively on the healthcare industry, announced today that ... the newly formed RoundTable III Platform Development Corporation ... Mr. Davies will focus his attention on the ...
... 5, 2012   Synteract , Inc., a full-service contract research ... as senior vice president of sales and marketing and has ... global project management, to support growth in the company and ... COO Stewart Bieler, and CFO Patrik Jeanmonod on the executive ...
Cached Medicine Technology:RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation 2Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3
(Date:5/28/2015)... Vancouver, BC (PRWEB) May 28, 2015 ... iData Research ( http://www.idataresearch.com ), the shoulder reconstruction ... the orthopedic small bone & joint market in ... of shoulder arthroplasty procedures in the U.S. due ... as improved device technology resulting in greater patient ...
(Date:5/28/2015)... Houston, Tx (PRWEB) May 28, 2015 ... and decision support company, announces that it will ... and pharmacogenomics (PGx) testing at the annual American ... weekend. , Next-generation sequencing evaluates the DNA in ... The DNA is analyzed for key changes or ...
(Date:5/28/2015)... Hexagon Geospatial is pleased to announce that ... spatial data and mapping services, is using Hexagon Geospatial ... for urban change assessments in Bernalillo County, New Mexico. ... Data Division implemented a countywide approach to generating pixel-resolution ... a variety of different digital aerial camera systems, BHI ...
(Date:5/28/2015)... May 28, 2015 Optimity Advisors ... implementing innovative models of care for healthcare organizations ... alternative reimbursements and help operationalize contracting and engagement ... unveils a bi-weekly series of seven “ OrangePapers” ... Based Contracting. Optimity is a strategy, operations and ...
(Date:5/28/2015)... Sacramento, PA (PRWEB) May 28, 2015 ... wishes and adventures. Each item on the ... absolutely impossible events, experiences and tasks that the owner ... is no right or wrong when it comes to ... starting a business, writing poems, publishing a book, seeing ...
Breaking Medicine News(10 mins):Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 3Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 3Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2
... February 22, 2011 The McKesson Foundation today ... grants as part of its Mobilizing for Healthsm initiative ... diseases through the use of mobile-phone technology. The Mobilizing ... support studies on diabetes care and management at six ...
... February 21, 2011 New research shows that ... and stroke risks may not have gotten approval from ... effects of fluid retention had been better understood. Fluid ... and strokes of medications such as Vioxx, Bextra, and ...
... using a convenient blood glucose test for diagnosing diabetes and ... Mott Children,s Hospital shows it,s not the best way to ... has become the preferred way to diagnose diabetes among the ... The simple test measures longer-term blood sugar levels -- without ...
... French . An electronic health record system ... more must be done to speed up the implementation of this ... in place effectively, doctors and front line health care workers and ... are the findings of an innovative new study assessing the effectiveness ...
... , TUESDAY, Feb. 22 (HealthDay News) -- People with ... others to develop shingles, according to a new study. ... in a painful rash with lesions. Though it was ... an increased risk for the condition, the researchers of the ...
... , TUESDAY, Feb. 22 (HealthDay News) -- Ignition devices ... the number of new arrests of drivers who were ... The team with the U.S. Centers for Disease Control ... ignition interlocks, devices that prevent someone from operating a ...
Cached Medicine News:Health News:McKesson Foundation awards $1.3 million in 6 Mobilizing for Health Research grants 2Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 2Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 3Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 4Health News:Convenient blood test not as effective for diagnosing diabetes in children 2Health News:E-health must be a priority, researchers say 2Health News:Car Ignition 'Interlocks' Thwart Alcohol-Impaired Drivers 2
Puntenney curved forceps, curved, smooth 10 mm platforms....
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Curved, very delicate, smooth jaws with platforms., ,Straight, very delicate, smooth jaws with platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Medicine Products: